• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2-advanced breast cancer patients

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    cfDNA.pdf
    Size:
    116.4Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Krastev, B.
    Rai, R.
    Bulat, I.
    Maglakelidze, M.
    Murias, C.
    Arkenau, H. T.
    Baird, R. D.
    Wardley, Andrew M
    Roylance, R.
    Crijanovschi, A.
    Gogiladze, M.
    Tao, W.
    Beelen, A. P.
    Sorrentino, J. A.
    Show allShow less
    Affiliation
    Department of Medical Oncology, MHAT for Women’s Health e Nadezhda, Sofia, Bulgaria;
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Background: Despite significant improvements in progression-free survival for patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with approved CDK4/6 inhibitors combined with fulvestrant, treatment is limited by neutropenia and gastrointestinal (GI) side effects. Lerociclib, dosed twice daily (BID) with no drug holiday in combination with fulvestrant, has a favorable safety profile with low rates of GI adverse events and Grade 3/4 neutropenia, as well as encouraging antitumor activity in pts with HR+/HER2- ABC (NCT02983071). Cell-free DNA (cfDNA) analysis in peripheral blood was conducted to characterize mechanisms of response and resistance in pts that received lerociclib and fulvestrant. Methods: Pts with pretreated ABC were enrolled across doses of lerociclib 200e650 mg once daily and 100e250 mg BID in combination with fulvestrant 500 mg. Peripheral blood samples were drawn and cfDNA was isolated at baseline, cycle 1 day 15, each time point when tumor assessments were performed during the treatmentperiod, and at the end of treatment. Samples were analyzed using the Guardant360 platform. Results: Currently, 58 pts have been evaluated at baseline, with 44 pts (75.9%) harboring at least one somatic single nucleotide variant (mutation) in the genes evaluated. Seventeen pts (29.3%) harbored mutations in PIK3CA, with H1047R being the most common (8/17, 47.1%). Seven pts (12.1%) harbored mutations in ESR1, with D583G being the most common (4/7, 57.1%). No pts had mutations in both ESR1 and PIK3CA at baseline. Additionally, 3 pts (5.2%), 2 pts (3.4%), and 1 pt (1.7%) had mutations in genes at baseline associated with CDK4/6 resistance (RB1, CCND1, and CCNE1, respectively). Additional analyses of cfDNA (cycle 1 day 15 and end of treatment) along with correlation of cfDNA dynamics with clinical response are ongoing and will be presented. Conclusions: The most common baseline mutations detected were PIK3CA and ESR1. Additional analyses, including cycle 1 day 15 change from baseline and correlation with clinical response, are anticipated to help elucidate predictors of response and/or resistance to the combination of lerociclib and fulvestrant in patients with HR+ ABC.
    Citation
    Krastev B, Rai R, Bulat I, Maglakelidze M, Murias C, Arkenau HT, et al. 278MO cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients. Annals of Oncology. 2020;31:S351-S2.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/623471
    DOI
    10.1016/j.annonc.2020.08.380
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2020.08.380
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2020.08.380
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.